Gennex Laboratories Reports Flat Performance Amid Sales Growth and Profit Decline in August 2025

Gennex Laboratories, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending June 2025. The results, declared on August 14, 2025, indicate a flat financial performance during this period. Notably, the company's evaluation has undergone a revision, with its score adjusting to 1 from 2 over the past three months.
On a positive note, Gennex Laboratories has demonstrated growth in net sales, which reached Rs 34.18 crore, reflecting a year-on-year increase of 20.69%. This suggests a favorable near-term sales trend. Additionally, the company's Debtors Turnover Ratio has reached its highest level in the last five half-yearly periods at 9.74 times, indicating improved efficiency in settling debts.

Conversely, the financial results reveal challenges as well. The Profit After Tax (PAT) for the latest six months stands at Rs 7.03 crore, showing a year-on-year decline of 21.23%. Furthermore, a significant portion of the company's income, 38.84% of Profit Before Tax (PBT), is derived from non-operating activities, raising concerns about the sustainability of its business model.

For more insights, Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.